Annual Research Review: Defining and treating pediatric treatment-resistant depression / Jennifer B. DWYER in Journal of Child Psychology and Psychiatry, 61-3 (March 2020)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.312-332 Titre : Annual Research Review: Defining and treating pediatric treatment-resistant depression Type de document : Texte imprimé et/ou numérique Auteurs : Jennifer B. DWYER, Auteur ; Argyris STRINGARIS, Auteur ; David A. BRENT, Auteur ; Michael H. BLOCH, Auteur Article en page(s) : p.312-332 Langues : Anglais (eng) Mots-clés : Depression  major depressive disorder  psychopharmacology  psychotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Adolescent major depressive disorder (MDD) is a significant health problem, associated with substantial morbidity, cost, and mortality. Depression is a significant risk factor for suicide, which is now the second leading cause of death in young people. Up to twenty per cent of adolescents will experience MDD before adulthood, and while a substantial proportion will improve with standard-of-care treatments (psychotherapy and medication), roughly one third will not. METHODS: Here, we have reviewed the literature in order to discuss the concept of treatment-resistant depression (TRD) in adolescence, examine risk factors, diagnostic difficulties, and challenges in evaluating symptom improvement, and providing guidance on how to define adequate medication and psychotherapy treatment trials. RESULTS: We propose a staging model for adolescent TRD and review the treatment literature. The evidence base for first- and second-line treatments primarily derives from four large pediatric clinical trials (TADS, TORDIA, ADAPT, and IMPACT). After two medications and a trial of evidence-based psychotherapy have failed to alleviate depressive symptoms, the evidence becomes quite thin for subsequent treatments. Here, we review the evidence for the effectiveness of medication switches, medication augmentation, psychotherapy augmentation, and interventional treatments (i.e., transcranial magnetic stimulation, electroconvulsive therapy, and ketamine) for adolescent TRD. Comparisons are drawn to the adult TRD literature, and areas for future pediatric depression research are highlighted. CONCLUSIONS: As evidence is limited for treatments in this population, a careful consideration of the known risks and side effects of escalated treatments (e.g., mood stabilizers and atypical antipsychotics) is warranted and weighed against potential, but often untested, benefits. En ligne : http://dx.doi.org/10.1111/jcpp.13202 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420 [article] Annual Research Review: Defining and treating pediatric treatment-resistant depression [Texte imprimé et/ou numérique] / Jennifer B. DWYER, Auteur ; Argyris STRINGARIS, Auteur ; David A. BRENT, Auteur ; Michael H. BLOCH, Auteur . - p.312-332. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.312-332 Mots-clés : Depression  major depressive disorder  psychopharmacology  psychotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Adolescent major depressive disorder (MDD) is a significant health problem, associated with substantial morbidity, cost, and mortality. Depression is a significant risk factor for suicide, which is now the second leading cause of death in young people. Up to twenty per cent of adolescents will experience MDD before adulthood, and while a substantial proportion will improve with standard-of-care treatments (psychotherapy and medication), roughly one third will not. METHODS: Here, we have reviewed the literature in order to discuss the concept of treatment-resistant depression (TRD) in adolescence, examine risk factors, diagnostic difficulties, and challenges in evaluating symptom improvement, and providing guidance on how to define adequate medication and psychotherapy treatment trials. RESULTS: We propose a staging model for adolescent TRD and review the treatment literature. The evidence base for first- and second-line treatments primarily derives from four large pediatric clinical trials (TADS, TORDIA, ADAPT, and IMPACT). After two medications and a trial of evidence-based psychotherapy have failed to alleviate depressive symptoms, the evidence becomes quite thin for subsequent treatments. Here, we review the evidence for the effectiveness of medication switches, medication augmentation, psychotherapy augmentation, and interventional treatments (i.e., transcranial magnetic stimulation, electroconvulsive therapy, and ketamine) for adolescent TRD. Comparisons are drawn to the adult TRD literature, and areas for future pediatric depression research are highlighted. CONCLUSIONS: As evidence is limited for treatments in this population, a careful consideration of the known risks and side effects of escalated treatments (e.g., mood stabilizers and atypical antipsychotics) is warranted and weighed against potential, but often untested, benefits. En ligne : http://dx.doi.org/10.1111/jcpp.13202 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420

Commentary: Are alpha-2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016) / Michael H. BLOCH in Journal of Child Psychology and Psychiatry, 57-9 (September 2016)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 57-9 (September 2016) . - p.1005-1007 Titre : Commentary: Are alpha-2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016) Type de document : Texte imprimé et/ou numérique Auteurs : Michael H. BLOCH, Auteur Article en page(s) : p.1005-1007 Langues : Anglais (eng) Mots-clés : tics  attention deficit hyperactivity disorder  clonidine  guanfacine Index. décimale : PER Périodiques Résumé : In this issue, Whittington et al. (2016) present a systematic review that reports the efficacy of three primary treatments for children with Tourette syndrome (TS) – (a) ?2-adrenergic receptor agonists; (b) antipsychotic medications; and (c) habit reversal training/comprehensive behavioral intervention. In this commentary, we highlight the large degree of heterogeneity observed in the meta-analysis of trials involving alpha-2 agonist medications and present possible explanations for the observed heterogeneity. Among these possible explanations is the possibility that presence of comorbid ADHD may moderate the efficacy of alpha-2 agonists in the treatment of tic disorder with the medications being more effective in patients with both conditions. The commentary reviews the evidence supporting this possible moderating effect of ADHD and discusses the implications for such a relationship. En ligne : http://dx.doi.org/10.1111/jcpp.12592 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292 [article] Commentary: Are alpha-2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016) [Texte imprimé et/ou numérique] / Michael H. BLOCH, Auteur . - p.1005-1007. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 57-9 (September 2016) . - p.1005-1007 Mots-clés : tics  attention deficit hyperactivity disorder  clonidine  guanfacine Index. décimale : PER Périodiques Résumé : In this issue, Whittington et al. (2016) present a systematic review that reports the efficacy of three primary treatments for children with Tourette syndrome (TS) – (a) ?2-adrenergic receptor agonists; (b) antipsychotic medications; and (c) habit reversal training/comprehensive behavioral intervention. In this commentary, we highlight the large degree of heterogeneity observed in the meta-analysis of trials involving alpha-2 agonist medications and present possible explanations for the observed heterogeneity. Among these possible explanations is the possibility that presence of comorbid ADHD may moderate the efficacy of alpha-2 agonists in the treatment of tic disorder with the medications being more effective in patients with both conditions. The commentary reviews the evidence supporting this possible moderating effect of ADHD and discusses the implications for such a relationship. En ligne : http://dx.doi.org/10.1111/jcpp.12592 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=292

Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020) / L. C. FARHAT in Journal of Child Psychology and Psychiatry, 62-6 (June 2021)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.701-703 Titre : Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020) Type de document : Texte imprimé et/ou numérique Auteurs : L. C. FARHAT, Auteur ; Michael H. BLOCH, Auteur Article en page(s) : p.701-703 Langues : Anglais (eng) Mots-clés : Atomoxetine Hydrochloride/pharmacology  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Child  Guanfacine/pharmacology  Humans  Methylphenidate/pharmacology Index. décimale : PER Périodiques Résumé : In this issue, Rodrigues et al. (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem. En ligne : http://dx.doi.org/10.1111/jcpp.13374 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455 [article] Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020) [Texte imprimé et/ou numérique] / L. C. FARHAT, Auteur ; Michael H. BLOCH, Auteur . - p.701-703. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.701-703 Mots-clés : Atomoxetine Hydrochloride/pharmacology  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Child  Guanfacine/pharmacology  Humans  Methylphenidate/pharmacology Index. décimale : PER Périodiques Résumé : In this issue, Rodrigues et al. (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem. En ligne : http://dx.doi.org/10.1111/jcpp.13374 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455

Editorial: Can omega-3 fatty acids improve executive functioning? Will this reduce ADHD and depression? / Bekir B. ARTUKOGLU in Journal of Child Psychology and Psychiatry, 59-6 (June 2018)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 59-6 (June 2018) . - p.615-617 Titre : Editorial: Can omega-3 fatty acids improve executive functioning? Will this reduce ADHD and depression? Type de document : Texte imprimé et/ou numérique Auteurs : Bekir B. ARTUKOGLU, Auteur ; Michael H. BLOCH, Auteur Article en page(s) : p.615-617 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Families with children who have neurodevelopmental disorders and mental health problems often opt to use nonmainstream and complementary medicines including dietary supplements. One dietary supplement popular with parents seeking treatment for both depression and ADHD is omega-3 fatty acids. This has led to much research and scientific debate dedicated to examining the efficacy of omega-3 supplementation as a treatment for both depression and ADHD. En ligne : http://dx.doi.org/10.1111/jcpp.12932 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=363 [article] Editorial: Can omega-3 fatty acids improve executive functioning? Will this reduce ADHD and depression? [Texte imprimé et/ou numérique] / Bekir B. ARTUKOGLU, Auteur ; Michael H. BLOCH, Auteur . - p.615-617. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 59-6 (June 2018) . - p.615-617 Index. décimale : PER Périodiques Résumé : Families with children who have neurodevelopmental disorders and mental health problems often opt to use nonmainstream and complementary medicines including dietary supplements. One dietary supplement popular with parents seeking treatment for both depression and ADHD is omega-3 fatty acids. This has led to much research and scientific debate dedicated to examining the efficacy of omega-3 supplementation as a treatment for both depression and ADHD. En ligne : http://dx.doi.org/10.1111/jcpp.12932 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=363

Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset / Rebecca C. KAMODY in Journal of Child Psychology and Psychiatry, 64-8 (August 2023)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 64-8 (August 2023) . - p.1101-1103 Titre : Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset Type de document : Texte imprimé et/ou numérique Auteurs : Rebecca C. KAMODY, Auteur ; Michael H. BLOCH, Auteur Article en page(s) : p.1101-1103 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The deleterious impact of the COVID-19 pandemic on youth mental health has garnered much attention (Newlove-Delgado et al., 2023). It has been a topic of interest in both research and academic writing, as well as in the public press (e.g., Tanner, 2023). Disorders and mental health concerns of focus have been wide-ranging, with some of the most severe presentations, such as suicidality, highlighted (Asarnow and Chung, 2021). Eating disorders are among the most life-threatening and prominent mental health concerns that have been exacerbated by the pandemic, and our current models of youth mental health care cannot keep up. Given this context, our team read and reviewed the manuscript, Shifting age of child eating disorder hospitalizations during the Covid-19 pandemic (Auger et al., 2023), eagerly. While the increasing severity of eating disorder presentations and increase in pediatric hospitalization has been an area of research (Asch et al., 2021), including at our own institution (Shum et al., 2022), the impact of age of onset, and the consequential impact on current systems of care, requires much greater attention. En ligne : https://doi.org/10.1111/jcpp.13852 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508 [article] Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset [Texte imprimé et/ou numérique] / Rebecca C. KAMODY, Auteur ; Michael H. BLOCH, Auteur . - p.1101-1103. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 64-8 (August 2023) . - p.1101-1103 Index. décimale : PER Périodiques Résumé : The deleterious impact of the COVID-19 pandemic on youth mental health has garnered much attention (Newlove-Delgado et al., 2023). It has been a topic of interest in both research and academic writing, as well as in the public press (e.g., Tanner, 2023). Disorders and mental health concerns of focus have been wide-ranging, with some of the most severe presentations, such as suicidality, highlighted (Asarnow and Chung, 2021). Eating disorders are among the most life-threatening and prominent mental health concerns that have been exacerbated by the pandemic, and our current models of youth mental health care cannot keep up. Given this context, our team read and reviewed the manuscript, Shifting age of child eating disorder hospitalizations during the Covid-19 pandemic (Auger et al., 2023), eagerly. While the increasing severity of eating disorder presentations and increase in pediatric hospitalization has been an area of research (Asch et al., 2021), including at our own institution (Shum et al., 2022), the impact of age of onset, and the consequential impact on current systems of care, requires much greater attention. En ligne : https://doi.org/10.1111/jcpp.13852 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508

Editorial: From adolescence into young adulthood - the importance of a longitudinal perspective across development in child and adolescent mental health / Julian KOENIG in Journal of Child Psychology and Psychiatry, 66-1 (January 2025)  

Permalink

Editorial: Money cannot buy happiness - but can it prevent depression? A commentary on Su et al / M. NASIR in Journal of Child Psychology and Psychiatry, 62-9 (September 2021)  

Permalink

Editorial: Reducing adolescent suicide / Michael H. BLOCH in Journal of Child Psychology and Psychiatry, 57-7 (July 2016)  

Permalink

Editorial: Schools on the frontline of suicide prevention / Rebecca C. KAMODY in Journal of Child Psychology and Psychiatry, 63-8 (August 2022)  

Permalink

Editorial: The continuing contributions of MTA over nearly two decades to initial attention-deficit hyperactivity disorder pharmacotherapy and long-term clinical course / Michael H. BLOCH in Journal of Child Psychology and Psychiatry, 58-6 (June 2017)  

Permalink

Fine-motor skill deficits in childhood predict adulthood tic severity and global psychosocial functioning in Tourette's syndrome / Michael H. BLOCH in Journal of Child Psychology and Psychiatry, 47-6 (June 2006)  

Permalink

Poor fine-motor and visuospatial skills predict persistence of pediatric-onset obsessive-compulsive disorder into adulthood / Michael H. BLOCH in Journal of Child Psychology and Psychiatry, 52-9 (September 2011)  

Permalink

Special Editorial: Open science and the Journal of Child Psychology & Psychiatry - next steps? / J. ASARNOW in Journal of Child Psychology and Psychiatry, 59-7 (July 2018)  

Permalink

Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders / Brian REICHOW in Journal of Autism and Developmental Disorders, 43-10 (October 2013)  

Permalink

---

1 (1 - 14 / 14)